Ampliphi Biosciences stock has rising large players volume after the company released incredible phase 1 trial results from their phage therapy cure for antibiotic resistant superbugs.
This website uses cookies to guarantee the best experience for the user. If you continue browsing, we consider that you agree to their use. For more information click here.
